Download User Guide

18 results returned.
Page   of  2

A 7196 (see companion bill S 5169) – New York
Introduced: 2019    Status: Inactive / Dead    
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.

A 7245 (see companion bill S 4370) – New York
Introduced: 2021    Status: In Process    
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, is to …

A 8824 (see companion bill S 398) – New York
Introduced: 2022    Status: In Process    
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.

AB 824 – California
Introduced: 2019    Status: Enacted    
Business: preserving access to affordable drugs – This bill would provide that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical …

H 4605 (replaced by H4617) – Massachusetts
Introduced: 2018    Status: Inactive / Dead    
AN ACT ESTABLISHING THE HONORABLE PETER V. KOCOT ACT TO ENHANCE ACCESS TO HIGH QUALITY, AFFORDABLE AND TRANSPARENT HEALTHCARE IN THE COMMONWEALTH.

H 4617 (replacd by H 4639) – Massachusetts
Introduced: 2018    Status: Inactive / Dead    
AN ACT ESTABLISHING THE HONORABLE PETER V. KOCOT ACT TO ENHANCE ACCESS TO HIGH QUALITY, AFFORDABLE AND TRANSPARENT HEALTHCARE IN THE COMMONWEALTH.

H 4639 – Massachusetts
Introduced: 2018    Status: Inactive / Dead    
AN ACT ESTABLISHING THE HONORABLE PETER V. KOCOT ACT TO ENHANCE ACCESS TO HIGH QUALITY, AFFORDABLE AND TRANSPARENT HEALTHCARE IN THE COMMONWEALTH.

HB 2754 – Oregon
Introduced: 2019    Status: Inactive / Dead    
Requires pharmacy or pharmacist to substitute prescribed biological product with interchangeable biological product. Declares emergency, effective on passage.

HB 345 – Montana
Introduced: 2021    Status: Inactive / Dead    
Establish Prescription Drug Pay-for-Delay Transparency Act. Each manufacturer of a brand-name prescription drug that is transacting business in this state or whose brand-name prescription drugs are otherwise sold or distributed in this state shall notify …

HB 7174 – Connecticut
Introduced: 2019    Status: Inactive / Dead    
To: (1) Establish the “Connecticut Prescription Drug Program” and the “Connecticut prescription drug program account”; (2) require pharmaceutical manufacturers to send notice to the Insurance Commissioner regarding “pay-for-delay” agreements, and require health carriers and pharmacy …

LD 1280 (see companion bill SP 432) – Maine
Introduced: 2017    Status: Enacted     Year Enacted: 2018
AN ACT REGARDING GENERIC DRUG PRICING. This bill amends the Maine Pharmacy Act to require that a drug distributed in this State must be made available for sale in this State to a person seeking …

S 398 (see companion bill A 8824) – New York
Introduced: 2022    Status: In Process    
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.

S 4370 (see companion bill A 7245) – New York
Introduced: 2021    Status: In Process    
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, is to …

S 5169 (see companion bill A 7196) – New York
Introduced: 2019    Status: Inactive / Dead    
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.

SB 188 – Connecticut
Introduced: 2022    Status: Inactive / Dead    
AN ACT REQUIRING BRAND NAME PRESCRIPTION DRUG MANUFACTURERS TO PROVIDE SAMPLES OF BRAND NAME DRUGS TO GENERIC PRESCRIPTION DRUG MANUFACTURERS. To promote competition in the prescription drug market by allowing developers of generic drugs and …

SB 764 – Oregon
Introduced: 2021    Status: Inactive / Dead    
Provides that court must presume that resolution agreement that ends dispute over alleged infringement of patent or violation of other protection for protected drug has anticompetitive effects if alleged infringer receives item of value as …

18 results returned.
Page   of  2

© 2018-2020 The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.